Post by PressReleaseon Sep 06, 2022 8:33am
30 Views
Post# 34943452
New Press Release - FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome